Autoimmunity modifying proteins - Aeterna Zentaris/Julius Maximilians University
Alternative Names: AIM biologicals - Aeterna Zentaris/Julius Maximilians UniversityLatest Information Update: 19 Jan 2023
At a glance
- Originator Julius-Maximilians University
- Developer AEterna Zentaris Inc; Julius-Maximilians University
- Class Antiparkinsonians; Eye disorder therapies; Eye proteins; Neuroprotectants
- Mechanism of Action Aquaporin 4 modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neuromyelitis optica; Parkinson's disease
Most Recent Events
- 17 Jan 2023 AEterna Zentaris plans a scientific advice meetings with regulatory authorities with comprehensive pre-clinical data package in the third quarter of 2023.
- 13 Jun 2022 Pharmacodynamics data from preclinical trial in Neuromyelitis optica released by Aeterna Zentaris
- 12 May 2022 Pharmacodynamics data from a preclinical study in Parkinson’s Disease released by AEterna Zentaris